Search or Ask Iris
Ctrl+K
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Gujarat Kidney and Super Speciality Limited is a regional healthcare provider in central Gujarat operating a chain of seven mid-sized multispeciality hospitals and four pharmacies. With a total capacity of 490 beds, the company focuses on delivering integrated secondary and tertiary care services across specialities like urology, cardiology, nephrology, and oncology. The company has a strategic focus on expanding its presence in underpenetrated markets within Gujarat through both organic growth and acquisitions.
Dec 22, 2025
Dec 24, 2025
Dec 30, 2025
Mainboard
Closed
250.8 Cr
0 Cr
0 Cr
—
—
The main objectives of the issue are to utilize the Net Proceeds for the following purposes:
Funding the proposed acquisition of 100% shareholding in 'Parekhs Hospital Private Limited' located in Ahmedabad to expand its geographical footprint and service offerings.
Making a part-payment of the purchase consideration for the recently completed acquisition of 'Ashwini Medical Centre' hospital in Anand.
Acquiring the remaining 49% shareholding in its subsidiary, 'Harmony Medicare Private Limited' at Bharuch, to make it a wholly-owned subsidiary.
Financing the capital expenditure for setting up a new 50-bed hospital in Vadodara dedicated to women's healthcare and well-being.
Purchasing a 'MAKO SmartRobotics TM System' for the Gujarat Kidney & Super Speciality Hospital in Vadodara to enhance its orthopaedics and surgical capabilities.
Full or partial repayment and/or prepayment of certain outstanding secured borrowings availed by the company to reduce debt and improve the debt-to-equity ratio.
Funding future inorganic growth through unidentified strategic acquisitions and for general corporate purposes to support business operations and expansion.
—
—
36.61%
37.65%
36.61%
—
23.61%
41.12%
—
Pre-eminence in renal sciences and urology, with established sub-specialities and a track record of complex procedures like renal transplants.
Operates an asset-light business model through leased properties and strategic acquisitions of operational hospitals, enabling faster expansion.
Strong ability to attract and retain skilled medical professionals, including doctors and nurses, supported by a reputable brand and founder.
Consistent track record of operational and financial growth, demonstrated by expanding hospital networks and positive profitability.
High revenue dependency on its Gujarat Kidney Hospital in Vadodara and significant regional concentration in central Gujarat.
Limited operating history as a consolidated entity, which may make it difficult to evaluate business performance and future prospects.
Lack of experience in executing greenfield projects, with reliance on third-party vendors for the construction of new hospitals.
Key hospitals operate on leased premises, posing a risk of disruption if lease agreements are not renewed on favorable terms.
Pursue strategic inorganic growth through acquisitions to further expand its geographical footprint within Gujarat and other regions.
Capitalize on the growing demand for quality healthcare driven by rising life expectancy and an increasing prevalence of non-communicable diseases.
Leverage the underpenetrated healthcare market in India, particularly in tier-II and tier-III cities, to expand services.
Benefit from the increasing health insurance penetration in India, which improves affordability and access to healthcare for a larger population.
The healthcare industry is highly regulated, and failure to comply with statutory permits and licenses could lead to penalties or operational disruptions.
Intense competition from established hospital chains and numerous unorganized local healthcare providers in the region.
Potential inability to attract and retain skilled healthcare professionals in a competitive market, which could affect service quality.
Risks of medical negligence claims, litigation, and adverse publicity, which can lead to reputational damage and financial liabilities.
Gujarat Kidney and Super Speciality Limited is a regional healthcare provider in central Gujarat operating a chain of seven mid-sized multispeciality hospitals and four pharmacies. With a total capacity of 490 beds, the company focuses on delivering integrated secondary and tertiary care services across specialities like urology, cardiology, nephrology, and oncology. The company has a strategic focus on expanding its presence in underpenetrated markets within Gujarat through both organic growth and acquisitions.
The Gujarat Kidney & Super Speciality Ltd. IPO is scheduled to open for subscription on Dec 22, 2025 and close on Dec 24, 2025. Investors can apply for shares during this period through eligible platforms.
The price band for the Gujarat Kidney & Super Speciality Ltd. IPO is yet to be announced. Investors can place bids within this range once the issue opens.
The minimum lot size for the Gujarat Kidney & Super Speciality Ltd. IPO is yet to be announced shares. The minimum investment amount will be known once the price band is finalized.
The total issue size of the Gujarat Kidney & Super Speciality Ltd. IPO is approximately ₹250.80. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Gujarat Kidney & Super Speciality Ltd. IPO has been subscribed data will be available once the issue opens. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Gujarat Kidney & Super Speciality Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Gujarat Kidney & Super Speciality Ltd. are expected to list on stock exchanges on Dec 30, 2025, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Gujarat Kidney & Super Speciality Ltd. IPO are proposed to be used for The main objectives of the issue are to utilize the Net Proceeds for the following purposes:, Funding the proposed acquisition of 100% shareholding in 'Parekhs Hospital Private Limited' located in Ahmedabad to expand its geographical footprint and service offerings., Making a part-payment of the purchase consideration for the recently completed acquisition of 'Ashwini Medical Centre' hospital in Anand., Acquiring the remaining 49% shareholding in its subsidiary, 'Harmony Medicare Private Limited' at Bharuch, to make it a wholly-owned subsidiary., Financing the capital expenditure for setting up a new 50-bed hospital in Vadodara dedicated to women's healthcare and well-being., Purchasing a 'MAKO SmartRobotics TM System' for the Gujarat Kidney & Super Speciality Hospital in Vadodara to enhance its orthopaedics and surgical capabilities., Full or partial repayment and/or prepayment of certain outstanding secured borrowings availed by the company to reduce debt and improve the debt-to-equity ratio., Funding future inorganic growth through unidentified strategic acquisitions and for general corporate purposes to support business operations and expansion.
Before applying for the Gujarat Kidney & Super Speciality Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
